EGFR and central nervous system cancer: Molecular profiling tools have advanced subtyping of gliomas based on genetic alterations observed in IDHwt LGG tumors regarding the reclassification of gliomas with MRI and histological findings consistent with diffuse astrocytomas grade II and III, whereby these tumors are now categorized as grade 4 tumors with molecular features of glioblastoma based on the presence of TERT promoter mutation, +7/−10, or EGFR amplification, according to the cIMPACT-NOW Update 3 [11,12,13,14].